A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.
Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN Jr, Tannir NM.
Jonasch E, et al.
Ann Oncol. 2017 Apr 1;28(4):804-808. doi: 10.1093/annonc/mdw676.
Ann Oncol. 2017.
PMID: 28049139
Free PMC article.
Clinical Trial.